This is a non-core endpoint: only basic statistics are computed.
See its core counterpart C3_KIDNEY_PAPILLARYADENO_EXALLC for full statistics.
Adenocarcinoma and Papillary adenocarcinoma of kidney
C3_KIDNEY_PAPILLARYADENO
No definition available.
Endpoint definition
↥
FinnGen phenotype data
429209 individuals
Apply sex-specific rule None
429209
Check conditions None
429209
Check pre-conditions, main-only, mode, registry filters
Cancer registry: Topography ICD-O-3
C64
Cancer registry: Morphology ICD-O-3
8260
Cancer registry: Behaviour codes
3
1 out of 7 registries used, show all original rules.
238
Check minimum number of events None
238
Include endpoints None
238
Remove individuals based on genotype QC
226
C3_KIDNEY_PAPILLARYADENO
Control definitions
Controls for this endpoint are individuals that are not cases.
Extra metadata
Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF9
Not enough data for upset plot.
Or the full data table
Similar endpoints
↥List of similar endpoints to
Adenocarcinoma and Papillary adenocarcinoma of kidney
based on the number of shared cases.
Broader endpoints:
- Adenocarcinoma and Papillary adenocarcinoma of kidney (controls excluding all cancers)
- Malignant neoplasm of kidney, except renal pelvis
- Malignant neoplasm of kidney, except renal pelvis (controls excluding all cancers)
- Malignant neoplasm of urinary organs
- Malignant neoplasm of urinary organs (controls excluding all cancers)
Narrower endpoints:
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 226 | 50 | 176 |
| Unadjusted prevalence (%) | 0.05 | 0.02 | 0.10 |
| Mean age at first event (years) | 65.35 | 66.77 | 64.95 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: C3_KIDNEY_PAPILLARYADENO – Adenocarcinoma and Papillary adenocarcinoma of kidney
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Adenocarcinoma and Papillary adenocarcinoma of kidney
↥Endpoint not on priority list, no data to show.